- Accesswire•28 days ago
Palatin Technologies to Present at The MicroCap Conference on April 4th at 1:00 PM ET in New York City at the Essex House
NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Palatin Technologies ( NYSE MKT: PTN ) will be presenting at this year's MicroCap Conference on April 4th in New York City. CONFERENCE OVERVIEW AND STRUCTURE ...
- PR Newswire•last month
Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
CRANBURY, N.J., March 20, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/704,223. The allowed claims are for methods of treating female sexual dysfunction and hypoactive sexual desire disorder (HSDD) with bremelanotide, an investigational product designed for on-demand treatment of HSDD in premenopausal women. Once issued, the patent will have a term to November 2033.
- PR Newswire•2 months ago
CRANBURY, N.J., March 9, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that it will be presenting at the 29 th Annual ROTH Conference on Tuesday, March 14, 2017, at 11:00 ...
PTN : Summary for Palatin Technologies, Inc. Comm - Yahoo Finance
Palatin Technologies, Inc. (PTN)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Day's Range||0.41 - 0.44|
|52 Week Range||0.29 - 0.90|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|